Neurodevelopment Genes Encoding Olduvai Domains Link Myalgic Encephalomyelitis to Neuropsychiatric Disorders.
Arcos-Burgos, Mauricio, Arcos-Holzinger, Mauricio, Mastronardi, Claudio et al. · Diagnostics (Basel, Switzerland) · 2025 · DOI
Quick Summary
Researchers compared DNA samples from 77 Australian ME/CFS patients with genetic databases to identify differences that might explain the disease. They found that certain genes involved in brain development—particularly those encoding special protein structures called Olduvai domains—were associated with ME/CFS. When they checked these findings in a separate U.S. patient group, they confirmed several of the same genetic associations, suggesting these genes may play a role in ME/CFS.
Why It Matters
This is among the first studies to identify specific genetic variants consistently associated with ME/CFS across independent patient populations, providing potential molecular leads for understanding disease mechanisms. The convergence on neurodevelopmental pathways connects ME/CFS to biological processes relevant to brain function, which may guide future diagnostic and therapeutic approaches.
Observed Findings
Significant associations in NBPF10 (p = 9.262 × 10⁻¹³), NBPF1 (p = 3.15 × 10⁻⁸), and NBPF16 (p = 1.04 × 10⁻⁶) in the Australian cohort.
Confirmed shared associations with PTPRD, CSMD3, RAPGEF5, DCC, ALDH18A1, GALNT16, UNC79, and NCOA3 in the U.S. replication cohort.
Identified variants in genes involved in cortical neurogenesis, brain evolution, and neuroblastoma that overlap with genetic associations in schizophrenia and autism.
Inferred Conclusions
ME/CFS has a genetic component linked to neurodevelopmental pathways, particularly those involved in brain structure and evolution.
The sharing of genetic associations across Australian and U.S. cohorts supports the validity of identified variants and suggests they represent genuine disease-associated loci.
The overlap between ME/CFS genetic associations and those found in schizophrenia and autism suggests potential shared neurobiological mechanisms across these conditions.
Remaining Questions
What are the functional consequences of these genetic variants, and how do they contribute to ME/CFS pathophysiology?
How do genetic predisposition and environmental triggers (such as infection) interact to cause disease in carriers of these variants?
Why are some carriers of these variants affected while others are not, and what modifiers determine disease penetrance?
What This Study Does Not Prove
This study does not prove that these genetic variants cause ME/CFS—it shows associations only. The findings do not establish whether variants are sufficient to cause disease, necessary for disease development, or simply markers of underlying biological pathways. Functional studies are needed to determine how these genes actually contribute to ME/CFS pathology.